olfactory receptor family 13 subfamily Z member 2 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR13Z2P profile across patient tissues and cancer cell-line models. OR13Z2P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, OR13Z2P is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, OR13Z2P RNA expression shows 11,911 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight DLBC, BLCA, and THYM as cancer lineages where OR13Z2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR13Z2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR13Z2P survival associations across molecular data types. OR13Z2P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR13Z2P RNA expression–survival associations across cancer types. High OR13Z2P expression shows unfavorable associations in DLBC, LIHC, THCA, KICH, CESC and ACC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for OR13Z2P RNA expression.
This table summarizes OR13Z2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR13Z2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR13Z2P shows higher tumor expression in BLCA, UCEC, HNSC, STAD, LUSC and LIHC. The BLCA box plot shows higher OR13Z2P RNA expression in tumor versus normal tissue (log2 FC = +0.172, t-test p < 0.001).
This table shows molecular features associated with OR13Z2P in patient tissues and cancer cell lines. In patient samples, OR13Z2P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
